199 related articles for article (PubMed ID: 32818453)
1. Immune therapies in ulcerative colitis: are we beyond anti-TNF yet?
Raine T; Verstockt B; De Cruz P
Lancet Gastroenterol Hepatol; 2020 Sep; 5(9):794-796. PubMed ID: 32818453
[No Abstract] [Full Text] [Related]
2. Tofacitinib for ulcerative colitis: results of the prospective Dutch Initiative on Crohn and Colitis (ICC) registry.
Biemans VBC; Sleutjes JAM; de Vries AC; Bodelier AGL; Dijkstra G; Oldenburg B; Löwenberg M; van Bodegraven AA; van der Meulen-de Jong AE; de Boer NKH; Srivastava N; West RL; Römkens TEH; Horjus Talabur Horje CS; Jansen JM; van der Woude CJ; Hoekstra J; Weersma RK; van Schaik FDM; Hoentjen F; Pierik MJ;
Aliment Pharmacol Ther; 2020 May; 51(9):880-888. PubMed ID: 32237087
[TBL] [Abstract][Full Text] [Related]
3. [Emerging Therapies: What Are Promising in the Near Future?].
Seo GS; Lee SH
Korean J Gastroenterol; 2018 Feb; 71(2):81-88. PubMed ID: 29471605
[TBL] [Abstract][Full Text] [Related]
4. Next generation of small molecules in inflammatory bowel disease.
Olivera P; Danese S; Peyrin-Biroulet L
Gut; 2017 Feb; 66(2):199-209. PubMed ID: 27856614
[No Abstract] [Full Text] [Related]
5. New Zealand Society of Gastroenterology Guidelines for the Management of Refractory Ulcerative Colitis.
Eliadou E; Day AS; Thompson-Fawcett MW; Gearry RB; Rowbotham DS; Walmsley R; Schultz M; Inns SJ; ;
N Z Med J; 2015 Oct; 128(1423):63-76. PubMed ID: 26645757
[TBL] [Abstract][Full Text] [Related]
6. Novel targets for inflammatory bowel disease therapeutics.
Löwenberg M; D'Haens G
Curr Gastroenterol Rep; 2013 Feb; 15(2):311. PubMed ID: 23314806
[TBL] [Abstract][Full Text] [Related]
7. Efficacy of tofacitinib treatment in ulcerative colitis.
Panés J; Gisbert JP
Gastroenterol Hepatol; 2019; 42(6):403-412. PubMed ID: 31101342
[TBL] [Abstract][Full Text] [Related]
8. Cost-Effectiveness of Different Strategies for the Treatment of Moderate-to-Severe Ulcerative Colitis.
Wu B; Wang Z; Zhang Q
Inflamm Bowel Dis; 2018 Oct; 24(11):2291-2302. PubMed ID: 29718241
[TBL] [Abstract][Full Text] [Related]
9. Safety comparison of therapies used in inflammatory bowel disease.
Pudipeddi A
J Gastroenterol Hepatol; 2021 Apr; 36 Suppl 1():20-21. PubMed ID: 33817854
[No Abstract] [Full Text] [Related]
10. Difference in treatment outcomes between clinical trials and "real-life" clinical practice: ustekinumab in ulcerative colitis.
Pugliese D; Armuzzi A
United European Gastroenterol J; 2020 Feb; 8(1):11-12. PubMed ID: 32213049
[No Abstract] [Full Text] [Related]
11. Comparative efficacy and safety of tocilizumab, rituximab, abatacept and tofacitinib in patients with active rheumatoid arthritis that inadequately responds to tumor necrosis factor inhibitors: a Bayesian network meta-analysis of randomized controlled trials.
Lee YH; Bae SC
Int J Rheum Dis; 2016 Nov; 19(11):1103-1111. PubMed ID: 26692536
[TBL] [Abstract][Full Text] [Related]
12. TOFACITINIB IN THE MANAGEMENT OF ULCERATIVE COLITIS REFRACTORY TO ANTI-TNF AND ANTI-INTEGRIN THERAPIES.
Teixeira FV; Damião AOMC; Kotze PG
Arq Gastroenterol; 2018; 55(2):198-200. PubMed ID: 30043874
[TBL] [Abstract][Full Text] [Related]
13. Managing Risks with Biologics.
Click B; Regueiro M
Curr Gastroenterol Rep; 2019 Jan; 21(2):1. PubMed ID: 30635807
[TBL] [Abstract][Full Text] [Related]
14. An economic evaluation of tofacitinib for the treatment of moderately-to-severely active ulcerative colitis: modeling the cost of treatment strategies in the United States.
Milev S; DiBonaventura MD; Quon P; Wern Goh J; Bourret J; Peeples-Lamirande K; Soonasra A; Cappelleri JC; Quirk D
J Med Econ; 2019 Sep; 22(9):859-868. PubMed ID: 31012362
[No Abstract] [Full Text] [Related]
15. Current and emerging biologics for ulcerative colitis.
Park SC; Jeen YT
Gut Liver; 2015 Jan; 9(1):18-27. PubMed ID: 25547087
[TBL] [Abstract][Full Text] [Related]
16. Recent trends and future directions for the medical treatment of ulcerative colitis.
Naganuma M; Mizuno S; Nanki K; Sugimoto S; Kanai T
Clin J Gastroenterol; 2016 Dec; 9(6):329-336. PubMed ID: 27699641
[TBL] [Abstract][Full Text] [Related]
17. A case of Takayasu arteritis complicated by refractory ulcerative colitis successfully treated with tofacitinib.
Sato S; Matsumoto H; Temmoku J; Fujita Y; Matsuoka N; Furuya M; Gunji N; Fujiwara T; Asano T; Onizawa M; Kobayashi H; Watanabe H; Ohira H; Migita K
Rheumatology (Oxford); 2020 Jul; 59(7):1773-1775. PubMed ID: 31776552
[No Abstract] [Full Text] [Related]
18. First Oral Drug for Moderate-To-Severe Ulcerative Colitis.
Aschenbrenner DS
Am J Nurs; 2018 Sep; 118(9):22-23. PubMed ID: 30138199
[No Abstract] [Full Text] [Related]
19. First-Line Biologics or Small Molecules in Inflammatory Bowel Disease: a Practical Guide for the Clinician.
Chang S; Hudesman D
Curr Gastroenterol Rep; 2020 Jan; 22(2):7. PubMed ID: 32002688
[TBL] [Abstract][Full Text] [Related]
20. The biologics of ulcerative colitis.
Macaluso FS; Renna S; Orlando A; Cottone M
Expert Opin Biol Ther; 2017 Feb; 17(2):175-184. PubMed ID: 27960557
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
